SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject2/28/2004 3:07:50 PM
From: nigel bates   of 631
 
DOMANTIS AND PEPTECH dAbs SHOW SUPERIOR POTENCY COMPARED WITH MARKETED PRODUCTS IN RHEUMATOID ARTHRITIS MODEL

Study confirms ability to extend dAb half-life and potential of dual targeting dAbs

Cambridge, UK and US, 26 February 2004… Domantis Limited, the leading Domain Antibody (dAb) therapeutics company, and Peptech Limited, the quoted Australian biotechnology company, today announced that their lead human anti-TNF alpha dAb proved significantly more potent than two marketed anti-TNF biologics in a pre-clinical model of rheumatoid arthritis. The research also established that the serum half-life of dAbs can be increased without affecting potency and demonstrated the in vivo potential of dual target dAbs for the first time.

Domantis’ Chief Scientific Officer and Co-Founder Dr Ian Tomlinson said, "We are delighted with these excellent results. The fact that we were able to exceed the therapeutic effect of two of the leading anti-TNF biologics in this model is further validation that dAbs will make potent drugs with genuine therapeutic advantages. Three different extended serum half-life dAb formats were evaluated during the study and all three demonstrated in vivo efficacy. Our ability to tailor the serum half-life of a therapeutic dAb to match the disease indication is key to delivering an effective dose whilst avoiding toxicity issues.”

Domantis also successfully evaluated a dual targeting dAb molecule as part of the research. Dual targeting molecules comprise two dAbs, each of which binds to a different target and produces a different biological effect. This is the first in vivo demonstration of dual targeting with dAbs.

Commenting on this aspect of the research, Ian Tomlinson said “One of the unique attributes of dAbs is their ability to be combined into a single drug that can hit two different therapeutic targets. Many diseases involve a number of different targets. Domantis’ dual targeting approach provides an effective solution to the treatment of such diseases and we are already working on several dual targeting products.”

Peptech Executive Chairman Mel Bridges said, “These impressive results illustrate why Peptech recently made a second investment in Domantis. The market for rheumatoid arthritis therapies in the seven major pharmaceutical markets is projected to grow to $6.6 billion by 2009. These results demonstrate the powerful therapeutic potential of dAbs in this area and the competitive advantages offered by these molecules. We continue to have great confidence in this collaborative project and in our investment”...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News